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Background: Clopidogrel loading is standard treatment for prevention of thrombotic events after primary stenting in acute myocardial infarction 
patients. However, sometimes problematic situations are encountered, such as patients with active gastrointestinal bleeding. Cilostazol has been 
found to recover platelet aggregation rapidly after drug withdrawal. At the current time little information is available to determine the effect of 
cilostazol compared to clopidogrel loading.
Methods: We retrospectively analyzed 220 consecutive patients (169 males, mean age 67±12 years) undergoing primary stenting for acute 
myocardial infarction. All patients were administered with aspirin (100mg once a day) and clopidogrel (75mg once a day). The patients were divided 
into two groups according to the presence (Loading group, n=100) or absence (Cilostazol group, n=120) of clopidogrel loading (300mg). The 
patients in Cilostazol group were administered adjunctive cilostazol (100 mg twice a day) in place of clopidogrel loading. Patient characteristics, 
medications and 30-day clinical outcomes were examined.
Results: The mean duration of cilostazol administration in Cilostazol group was 6.2±4.7 days from the time of primary coronary intervention. No 
significant difference was observed in major adverse cardiac events (cardiac death, definite stent thrombosis, and non-fatal myocardial infarction) 
between Loading group and Cilostazol group (8/100; 8.0% vs 9/120; 7.5%, p=0.89). Definite stent thrombosis was observed for 2 patients (2.0%) 
in Loading group and 4 patients (3.3%) in Cilostazol group. The occurrence ratio of stroke and bleeding events did not differ significantly between 
the two groups (2.0% vs 1.7% and 4.0% vs 4.2%, respectively).
Conclusions: Adjunctive cilostazol might have equivalent effect of clopidogrel loading in acute myocardial infarction patients undergoing primary 
stenting and receiving dual anti-platelet therapy. Our finding suggests one potential of cilostazol.
